MOD-4023
Total Payments
$298,245
Transactions
23
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $298,245 | 23 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $298,245 | 23 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY | OPKO Pharmaceuticals, LLC | $274,542 | 0 |
| Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency | OPKO Pharmaceuticals, LLC | $13,754 | 0 |
| Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children | OPKO Pharmaceuticals, LLC | $9,950 | 0 |
Top Doctors Receiving Payments for MOD-4023
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Aurora, CO | $298,245 | 23 |
Ad
Manufacturing Companies
- OPKO Pharmaceuticals, LLC $298,245
Product Information
- Type Drug
- Total Payments $298,245
- Total Doctors 0
- Transactions 23
About MOD-4023
MOD-4023 is a drug associated with $298,245 in payments to 0 healthcare providers, recorded across 23 transactions in the CMS Open Payments database. The primary manufacturer is OPKO Pharmaceuticals, LLC.
Payment data is available from 2020 to 2020. In 2020, $298,245 was paid across 23 transactions to 0 doctors.
The most common payment nature for MOD-4023 is "Unspecified" ($298,245, 100.0% of total).
MOD-4023 is associated with 3 research studies, including "A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY" ($274,542).